Table 4 Autoantibody prevalence in serum from patients with systemic lupus erythematosus in relation to anti-Toxoplasma gondii antibodies immunoglobulin G
Autoantibodiesa | All patients (n = 863) | ATxA-IgG+ SLE patients (n = 144) | ATxA-IgG− SLE patients (n = 719) | P valueb |
|---|---|---|---|---|
ANA positive, n (%) | 669 (88.5%) | 107 (88.4%) | 562 (88.5%) | 0.981 |
ANUA positive, n (%) | 417 (54.4%) | 76 (62.3%) | 341 (53.0%) | 0.057 |
Anti-rRNP positive, n (%) | 246 (37.3%) | 51 (47.7%) | 195 (35.3%) | 0.016* |
Anti-Ro/SSA positive, n (%) | 349 (46.7%) | 59 (49.6%) | 290 (46.2%) | 0.495 |
Anti-La/SSB positive, n (%) | 87 (11.6%) | 14 (15.9%) | 73 (11.6%) | 0.960 |
Anti-dsDNA positive, n (%) | 518 (65.4%) | 97 (75.2%) | 421 (63.5%) | 0.011* |
Anti-cmDNA positive, n (%) | 33 (5.4%) | 13 (13.5%) | 20 (3.9%) | 0.00011* |
Anti-Sm positive, n (%) | 142 (19.1%) | 29 (19.1%) | 113 (18.1%) | 0.113 |
Anti-Scl-70, n (%) | 22 (4.4%) | 7 (9.5%) | 15 (3.5%) | 0.021* |
Rheumatoid factor (RF), n (%) | 93 (12.9%) | 22 (19.0%) | 71 (11.8%) | 0.035* |
Anti-CL, n (%) | 134 (19.2%) | 36 (32.4%) | 98 (16.7%) | 0.00011* |
Anti-B2GPI, n (%) | 78 (11.1%) | 18 (16.8%) | 60 (10.1%) | 0.041* |